United KingdomTraders keep repositioning ahead of “Antimicrobial resistance push”
Positioning on Pharma R&D has become clearly one-sided ahead of “Antimicrobial resistance push”.
Event on Nov 26 · in 4 weeks
The prediction, in plain language
Too close to callIt is a coin flip, two scenarios, equally credible: the milestone is reached, or the milestone slips further out.
No betting price here, markets point this way with a signal strength of 48/100, stable in 24h, low confidence.
Treat this as a weak indication, not a forecast: confidence is low and the reading moves a lot.
This is what market prices currently imply, not a certainty. Readings change as new information arrives.
+0 / 24h
Confidence: Low
Sign in to follow this signal and set alerts.
Sign inWhy this signal
Data, Pharma R&D strengthened by 2 points over 24 hours, cross-checked against 2 linked markets.
Context, Research funding, patents and specialist suppliers are where science becomes measurable.
Interpretation, Taken together, prices point to a clear directional bias and a signal strength of 54/100 on this event.
Uncertainty, Confidence is low. This is what prices imply today, not a forecast, one surprise can reverse it.
Cross-market confirmation
Pharma R&D
+2
Public funding
in line
What could change it
- Peer-reviewed publication
- Public funding decision
Follow the story
Loading the latest headlines…
